Raymond James Financial Services Advisors Inc. Acquires 3,374 Shares of argenx SE (NASDAQ:ARGX)

Raymond James Financial Services Advisors Inc. grew its stake in argenx SE (NASDAQ:ARGX - Free Report) by 30.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,470 shares of the company's stock after purchasing an additional 3,374 shares during the period. Raymond James Financial Services Advisors Inc.'s holdings in argenx were worth $5,505,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Nkcfo LLC grew its stake in shares of argenx by 22.1% in the 3rd quarter. Nkcfo LLC now owns 116 shares of the company's stock valued at $57,000 after purchasing an additional 21 shares during the period. Genus Capital Management Inc. grew its position in argenx by 1.6% during the 3rd quarter. Genus Capital Management Inc. now owns 1,605 shares of the company's stock worth $789,000 after acquiring an additional 25 shares during the last quarter. Creative Planning grew its position in argenx by 3.0% during the 4th quarter. Creative Planning now owns 1,006 shares of the company's stock worth $381,000 after acquiring an additional 29 shares during the last quarter. Snowden Capital Advisors LLC grew its position in argenx by 1.9% during the 1st quarter. Snowden Capital Advisors LLC now owns 1,920 shares of the company's stock worth $715,000 after acquiring an additional 35 shares during the last quarter. Finally, KB Financial Partners LLC grew its position in argenx by 112.5% during the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company's stock worth $27,000 after acquiring an additional 45 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ARGX shares. Wells Fargo & Company increased their price target on argenx from $472.00 to $478.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 20th. Scotiabank upped their price objective on argenx from $402.00 to $408.00 and gave the stock a "sector perform" rating in a report on Tuesday, March 26th. William Blair downgraded argenx from an "outperform" rating to a "market perform" rating in a report on Wednesday, December 20th. Piper Sandler upped their price objective on argenx from $518.00 to $522.00 and gave the stock an "overweight" rating in a report on Friday, January 26th. Finally, Evercore ISI reduced their price objective on argenx from $594.00 to $436.00 and set an "outperform" rating on the stock in a report on Thursday, December 21st. One analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, argenx has an average rating of "Moderate Buy" and a consensus target price of $530.74.

argenx Trading Up 0.0 %

ARGX stock traded up $0.15 during mid-day trading on Friday, hitting $387.03. The stock had a trading volume of 122,818 shares, compared to its average volume of 335,700. argenx SE has a 52 week low of $327.73 and a 52 week high of $550.76. The firm has a market capitalization of $22.95 billion, a P/E ratio of -75.30 and a beta of 0.65. The firm has a fifty day simple moving average of $390.48 and a 200 day simple moving average of $429.55.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, February 29th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.45). argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. The firm had revenue of $417.84 million during the quarter, compared to the consensus estimate of $378.60 million. During the same period in the prior year, the business earned ($0.70) earnings per share. As a group, equities analysts expect that argenx SE will post -2 earnings per share for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.